Key Highlights
- Telomir Pharmaceuticals shares closed up 10% at $1.23.
- The company published peer-reviewed preclinical data evaluating Telomir-Zn in age-related macular degeneration.
- The data demonstrated regulated iron and copper levels, preserved retinal structure, and improved visual metrics.
- Lead development remains centered on oncology, headlined by an upcoming Phase 1/2 study in triple-negative breast cancer.
Telomir Pharmaceuticals, Inc. (NASDAQ: TELO) shares closed up 10% at $1.23 after the company published peer-reviewed preclinical data evaluating Telomir-Zn in age-related macular degeneration, demonstrating regulated iron and copper levels, preserved retinal structure, improved visual metrics, and decreased mitochondrial oxidative stress in models.
Company Overview
Telomir Pharmaceuticals is a preclinical and early clinical-stage biotechnology company focused on developing therapies targeting metal ion dysregulation as a driver of aging-related and other diseases. Its lead compound, Telomir-Zn, is a small molecule designed to regulate iron and copper levels in the body, mechanisms the company believes are implicated in a range of conditions, including both ocular diseases and certain cancers.
While this AMD data demonstrates the breadth of Telomir-Zn's potential applications, the company has indicated that its lead development priority remains oncology, with an upcoming Phase 1/2 study targeting advanced or metastatic triple-negative breast cancer representing the more immediate focus of its clinical development resources.
What Happened
While showing potential in ocular indications, lead development remains centered on oncology, headlined by an upcoming Phase 1/2 study targeting advanced or metastatic triple-negative breast cancer.
Market Reaction
Shares rose as investors responded to the peer-reviewed validation of Telomir-Zn's mechanism across a new indication, even though the company's primary near-term clinical focus remains its oncology program rather than ophthalmology.
Outlook
The upcoming Phase 1/2 study in advanced or metastatic triple-negative breast cancer represents the next major disclosed clinical milestone for Telomir Pharmaceuticals, with the AMD preclinical data serving as a longer-term pipeline expansion signal rather than an immediate development priority.






Please wait processing your request...